Aquestive Therapeutics, Inc. (AQST) Q3 2025 Earnings Call

Concluded Nov 5, 2025

Nov 5, 2025 0 turns

Period: FY2025 Q3
Runtime: —
Sources: 3 artifacts

Slides 10 8-K 10-Q

Executive readout · one minute

Webcast research workspace

Read the call alongside every captured source. slides, 8-K earnings release, 10-Q stay in one workspace.

Pipeline program AQST-108 / Adrenaverse 28 Anifilm FDA resubmission and review timing 23 Commercial launch preparation 16 Zebra royalty / Sympazan economics 13 Regulatory interactions (MHRA, EMA, Health Canada) 12 Capital position and Oaktree debt facility 10

Management tone

Positive

Net tone +45 · moderate hedging

Grounding quotes

“we continue to guide to a third quarter resubmission to the FDA, recognizing this timing remains subject to FDA feedback and ongoing review processes”
“We will request an expedited review upon our submission and will do everything we can to communicate with the FDA and support their review process, recognizing that any decision on review timing rests solely with the FDA”
“This, of course, cannot be guaranteed”
“we currently project that we will have greater than $150 million in cash at launch”

Research coverage

3 live sources

Open each available source without leaving this research workspace.

Revenue $12.81M -5.4% YoY

Diluted EPS -$0.14

Net income -$15.45M